INNT News and Press, Innovate Biopharmaceuticals Inc. From 02/07/19

RALEIGH, N.C., Feb. 07, 2019 (GLOBE NEWSWIRE) -- Innovate Biopharmaceuticals, Inc. (Nasdaq: INNT) a clinical stage biotechnology company focused on developing novel autoimmune and inflammation therapeutics, announced its intent to present at the BIO CEO & Investor Conference tak...

CNBC reports that nonalcoholic steatohepatitis or NASH is "next big thing" for drug makers, a potential market of $35B or more if pharma/biotech firms can successfully navigate the regulatory process, a task none has accomplished to date. More news on: Intercept Pharmaceuticals, Madrigal...

Preliminary top-line data from the alcoholic steatohepatitis (ASH) collaboration with Massachusetts General Hospital shows positive effect of larazotide on ethanol-induced permeability in vitro RALEIGH, N.C., Dec. 17, 2018 (GLOBE NEWSWIRE) -- Innovate Biopharmaceuticals Inc ...

RALEIGH, N.C., Nov. 05, 2018 (GLOBE NEWSWIRE) -- Innovate Biopharmaceuticals, Inc. (Innovate) (Nasdaq: INNT), a clinical stage biotechnology company focused on developing novel therapeutics for autoimmune and inflammatory diseases, today announced it intends to present at the BIO-Europe C...

RALEIGH, N.C., Oct. 31, 2018 (GLOBE NEWSWIRE) -- Innovate Biopharmaceuticals, Inc. (“Innovate”) (Nasdaq: INNT), a clinical stage biotechnology company focused on developing novel therapeutics for autoimmune and inflammatory diseases, today announced it intends to present at ...

Red Hat (NYSE: RHT ) +49%  on being acquired by IBM. More news on: Red Hat, Inc., Diana Containerships Inc., China Recycling Energy Corporation, Stocks on the move, , Top stock market news, Read more ...

Micro cap Innovate Biopharmaceuticals (NASDAQ: INNT ) is up  12%  premarket on modest volume on the heels of its announcement of encouraging preclinical data on lead candidate larazotide acetate in a mouse NASH model. The data showed a positive effect on reducing gut barrier perm...

Top line results showed larazotide having a significant effect on intestinal permeability, a mechanism thought to be key for bacterial translocation leading to NAFLD/NASH Further preclinical data in combination with approved drugs in development for NASH liraglutide (VICTOZA ® ) ...

RALEIGH, N.C., Sept. 06, 2018 (GLOBE NEWSWIRE) -- Innovate Biopharmaceuticals, Inc. (Nasdaq: INNT), a clinical stage biotechnology company focused on developing novel therapeutics for autoimmune and inflammatory diseases, plans to host an event on Thursday, September 6, 2018, in New York fr...

Gainers:  MNKD +57% . NCTY +29% . TA +29% . REPH +21% . CADC +20% . CDZI +18% . KNSA +16% . EPIX +15% . INNT +14% . NBEV +13% . More news on: MannKind Corporation, The9 Limited, TravelCenters of America LLC, Stocks on the move, , Read more ...